8 hrs ago
Insider Buying: Michael Narachi Acquires 50,000 Shares of Orexigen Therapeutics Stock
Orexigen Therapeutics CEO Michael Narachi acquired 50,000 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was purchased at an average price of $4.78 per share, with a total value of $239,000.00.
Fri Sep 12, 2014
NBC San Diego
Orexigen's Contrave Approved by FDA
The U.S. Food and Drug Administration has approved a weight-loss drug developed by La Jolla-based Orexigen Therapeutics Inc. Orexigen is partnered with Japanese pharmaceutical giant, Takeda Pharmaceutical Company Ltd., to manage marketing and sales of the new drug, Contrave. Takeda has assigned 900 sales representatives to the launch.
Thu Sep 11, 2014
Orexigen Therapeutics Price Target Raised to $15.00
Wells Fargo & Co.' s price objective would indicate a potential upside of 154.24% from the stock's previous close.
Applied Clinical Trials
Takeda and Orexigen Announce FDA Approval of Contrave? (naltrexone...
Takeda and Orexigen Announce FDA Approval of Contrave? Extended-release Tablets for Chronic Weight Management Takeda and Orexigen Announce FDA Approval of Contrave Extended-release Tablets for Chronic Weight Management , Inc. and Orexigen Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater , or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition.
Wed Sep 10, 2014
FDA approves a third new weight-loss pill
For the third time in about two years, the Food and Drug Administration has approved a new weight-loss pill. Contrave got FDA approval Wednesday.
Orexigen Therapeutics to Host Conference Call and Webcast At 8:30 AM Eastern Time September 11, 2014
The webcast can be accessed live on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.
Weight-loss drug clears FDA hurdle
Novo Nordisk's drug, to be named Saxenda, helped 60 percent of patients studied lose at least 5 percent of their weight and 31 percent lose more than 10 percent, according to a report Tuesday by the U.S. Food and Drug Administration staff.
Thu Sep 04, 2014
Orexigen Therapeutics Research Coverage Started at Credit Suisse
The firm set an "outperform" rating and a $10.00 price target on the stock. Credit Suisse's target price indicates a potential upside of 71.82% from the stock's previous close.
Wed Sep 03, 2014